Abstracts Archive - Page 1812 of 2607 - ACR Meeting Abstracts

Abstract Number: 3200 • 2016 ACR/ARHP Annual Meeting
Immunoscintigraphic Detection Of Tumor Necrosis Factor By Radiolabeled Certolizumab Pegol in Patients with Erosive Hand Osteoarthritis in Relation to Disease Activity: A Proof of Concept Study
Ruth Wittoek¹, Philippe Carron², Bieke Lambert³, Paulien Meersseman¹, Gust Verbruggen¹, Filip van Den Bosch¹ and Dirk Elewaut⁴, ¹Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Department of Nuclear Medicine Ghent University Hospital, Department of Nuclear Medicine Ghent University Hospital, Ghent, Belgium, ⁴Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium
Background/Purpose: A recent randomized clinical trial in erosive osteoarthritis (OA) of finger joints with a TNF blocking agent, adalimumab, showed inhibition of radiographic progression…
Abstract Number: 3201 • 2016 ACR/ARHP Annual Meeting
Diagnostic Value of Quantitative Sialoscintigraphy Compared to Labial Salivary Gland Biopsy in Patients with Suspected SjöGren’ Syndrome
Maria Garcia-Gonzalez¹, Maria Jesus Gonzalez-Soto², Ivan Ferraz-Amaro¹, Hiurma Sanchez¹, Vanesa Hernandez¹, Maria Angeles Gomez² and Sagrario Bustabad¹, ¹Rheumatology, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ²Nuclear Medicine, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain
Background/Purpose: Salivary gland dysfunction is one of the most common features of Sjögren' syndrome (SS). Sialoscintigraphy (sSC) is the only technique nowadays available to objectify…
Abstract Number: 3202 • 2016 ACR/ARHP Annual Meeting
Clinical and Ultrasonographic Evaluation of Joint Involvement in Patients with Systemic Sclerosis
María Victoria Martire¹, Priscila Marcaida², Santiago Scarafia³, Gloria Crespo², Anastasia Secco⁴, Lida Santiago² and Marta Mamani², ¹Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ²Hospital Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Argentina, ³Hospital Bernardino Rivadavia, CABA, Argentina, ⁴Hospital Bernardino Rivadavia, Buenos Aires, Argentina
Background/Purpose: Systemic sclerosis is a multisystem disease characterized by the development of microangiopathy and subsequent fibrosis of skin and internal organs. The joint involvement is…
Abstract Number: 3203 • 2016 ACR/ARHP Annual Meeting
Analysis of Efficacy and Safety of Cyclophosphamide in Juvenile Dermatomyositis Using a Large National UK Cohort
Claire Deakin¹, Raquel Campanilho-Marques², Stefania Simou³, Elena Moraitis⁴, Eleanor Pullenayegum^5,6, Lucy R Wedderburn^4,7,8, Clarissa Pilkington⁹ and Juvenile Dermatomyositis Research Group (JDRG), ¹Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, ²Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, Portugal, ³Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁴Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁵Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, ⁶Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁷Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁹Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Background/Purpose: Cyclophosphamide (CYC) has been used as a second-line agent in the treatment of severe or refractory JDM. The published literature on the efficacy of…
Abstract Number: 3204 • 2016 ACR/ARHP Annual Meeting
Body Composition and Adipose Tissue Distribution in Juvenile Dermatomyositis and Associations with Cardiac Function
Birgit Nomeland Witczak¹, Kristin Godang², Thomas Schwartz³, Nicoleta Cristina Olarescu⁴, Berit Flatø^5,6, Jens Bollerslev^5,7, Ivar Sjaastad^5,8,9 and Helga Sanner^5,6, ¹Oslo University Hospital, Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²Department of Specialised Endocrinology, Oslo University Hospital, Section of Specialised Endocrinology, Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ³Department of Infectious Diseases, Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway., Section of Specialised Endocrinology, Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ⁵Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, ⁶Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ⁷Section of Specialised Endocrinology, Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ⁸Department of Cardiology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁹Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Lipodystrophy and metabolic abnormalities occur frequently in juvenile dermatomyositis (JDM) and redistribution of adipose tissue has been reported in several rheumatic diseases. Visceral adipose…
Abstract Number: 3205 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD AND TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial
Fabrizio De Benedetti¹, Jordi Anton², Eldad Ben-Chetrit³, Inmaculada Calvo⁴, Joost Frenkel⁵, Marco Gattorno⁶, Hal M. Hoffman⁷, Ozgur Kasapcopur⁸, Isabelle Koné-Paut⁹, Helen Lachmann¹⁰, Michel Moutschen¹¹, Seza Ozen¹², Pierre Quartier¹³, Anna Simon¹⁴, Andrew Zeft¹⁵, Karine Lheritier¹⁶, Antonio Speziale¹⁶ and Guido Junge¹⁶, ¹IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ²Hospital Sant Joan de Déu, Barcelona, Spain, ³Rheumatology Unit, Hadassah—Hebrew University Medical Center, Jerusalem, Israel, ⁴Hospital Universitario y Piltecnico La Fe, Valencia, Spain, ⁵University Medical Center Utrecht, Utrecht, Netherlands, ⁶Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy, ⁷University of California at San Diego, San Diego, CA, ⁸Department of Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ⁹Hopital Kremlin Bicetre, University of Paris SUD, Paris, France, ¹⁰UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹¹C.H.U. Sart-Tilman, Liege, Belgium, ¹²Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹³Hôpital Necker-Enfants Malades, Paris, France, ¹⁴General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁵Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Periodic fever syndromes (PFS) are rare auto-inflammatory conditions that include, among others, cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), hyper-IgD syndrome/mevalonate kinase deficiency…
Abstract Number: 3206 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Childhood Vaccinations in CAPS Patients Treated with Canakinumab: Results from an Open-Label Phase III Extension Study
Paul Brogan¹, Michaël Hofer², Jasmin B. Kuemmerle-Deschner³, Bernard Lauwerys⁴, Antonio Speziale⁵, Xiaoling Wei⁶ and Ronald Laxer⁷, ¹Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ²Pediatrie, Unité Romande de Rhumatologie Pédiatrique, Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³University Hospital Tuebingen, Tuebingen, Germany, ⁴Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Shanghai Novartis Trading Limited, Shanghai, China, ⁷Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Canakinumab (CAN) has been shown not to impair antibody production following vaccination in children in an open-label phase 3 study (NCT01302860).1 Here we present…
Abstract Number: 3207 • 2016 ACR/ARHP Annual Meeting
The Deficiency of Adenosine Deaminase Type 2 (DADA2)—Results of Anti-TNF Treatment in a Cohort of Patients with a History of Stroke
Amanda K. Ombrello¹, Karyl Barron², Patrycja Hoffmann¹, Camilo Toro³, Deborah L. Stone⁴, Gineth Pinto-Patarroyo⁴, Anne Jones⁴, Tina Romeo⁵, Ariane Soldatos⁶, Qing Zhou⁷, Natalie Deuitch⁵, Jing Qin², Ivona Aksentijevich⁴ and Daniel L. Kastner⁴, ¹Inflammatory Diseases Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ³NIH Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁴Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁵National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁶National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, ⁷Inflammatory Disease Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: The deficiency of adenosine deaminase type 2 (DADA2) is an autosomal recessive disease resulting from biallelic mutations in CECR1. Patients commonly present with vascular…
Abstract Number: 3208 • 2016 ACR/ARHP Annual Meeting
Preliminary Response to JAK1/2 Inhibition with Baricitinib in “Candle”,“Savi” and “Candle-like” Diseases. a New Therapeutic Approach for Type I IFN Mediated Autoinflammatory Diseases
Gina A. Montealegre Sanchez¹, Adam Reinhardt², Paul Brogan³, Dawn C. Chapelle⁴, Hanna Kim⁴, Samantha Judd⁴, Bahar Kost⁴, Michelle O'Brien⁴, Wendy Goodspeed⁵, Robert A. Colbert⁴, Meryl Waldman⁶, Deborah L. Stone⁷, Ling Gao⁸, JA Dare⁸, Susanne Schalm⁹, Thomas L. Klausmeier¹⁰, Sara Murias¹¹, Yackov Berkun¹², Diane Brown¹³, John D. Carter¹⁴, Fehime K Eroglu¹⁵, A. Zlotogorski¹⁶, Philip Hashkes¹⁷, Helmut Wittkowski¹⁸, Suzanne Ramsey¹⁹, Seza Ozen²⁰, Adriana Almeida de Jesus²¹ and Raphaela Goldbach-Mansky²², ¹NIAID/NIH, Bethesda, MD, ²Rheumatology, Children's Hosp of Omaha/UNMC, Omaha, NE, ³UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁴NIAMS/NIH, Bethesda, MD, ⁵Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, ⁶NIDDK/NIH, Bethesda, MD, ⁷NHGRI/NIH, Bethesda, MD, ⁸University of Arkansas for Medical Sciences, Little Rock, AR, ⁹LMU Munich, Munich, Germany, ¹⁰Riley Hospital for Children, Indianapolis, IN, ¹¹Hospital Infantil La Paz, Madrid, Spain, ¹²Hadassah-Hebrew University Medical Center, Jerusalem, Israel, ¹³Children's Hospital Los Angeles, Los Angeles, CA, ¹⁴Division of Rheumatology, University of South Florida, Tampa, FL, ¹⁵Department of Pediatrics, Hacettepe University Hospitals, Ankara, Turkey, ¹⁶Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, ¹⁷Pediatric Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, ¹⁸Pediatrics, University of Muenster, Muenster, Germany, ¹⁹Pediatric Rheumatology, IWK Health Centre, Halifax, NS, Canada, ²⁰Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²¹National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²²Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: Chronically elevated serum IP-10 (CXCL10) levels, and a prominent “interferon (IFN)-response gene signature” in patients with chronic neutrophilic dermatosis with lipodystrophy and elevated temperatures…
Abstract Number: 3209 • 2016 ACR/ARHP Annual Meeting
Clinical and Radiological Outcomes of 5 Years Remission Steered Treatment in Early Rheumatoid and Undifferentiated Arthritis Patients
Gülsah Akdemir¹, L. Heimans², R.J. Goekoop³, Maikel van Oosterhout⁴, J.B. Harbers⁵, C. Bijkerk⁶, G.M. Steup-Beekman⁷, L.R. Lard⁸, P.B.J. de Sonnaville⁹, B.A.M. Grillet¹⁰, TWJ Huizinga¹¹ and Cornelia F. Allaart², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Haga Hospital, The Hague, Netherlands, ⁴Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Department of Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, ⁶Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁷Rheumatology, Bronovo Hospital, The Hague, Netherlands, ⁸Rheumatology, MCH Antoniushove Hospital, Leidschendam, Netherlands, ⁹Rheumatology, ADRZ, Goes, Netherlands, ¹⁰Rheumatology, Zorgsaam, Terneuzen, Netherlands, ¹¹Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: To assess clinical and radiological outcomes of induction therapy followed by 5 years disease activity score (DAS)-remission steered treatment in early arthritis patients. Methods:…
Abstract Number: 3210 • 2016 ACR/ARHP Annual Meeting
10+ Years’ Follow-up of a Danish 2-Year Treat-to-Target RCT in Patients with Early Rheumatoid Arthritis: Baseline Predictors of Functional and Radiographic Outcomes
Merete Lund Hetland¹, Kristian Stengaard-Pedersen², Peter Junker¹, Hanne Lindegaard¹, Torkell Ellingsen¹, Jan Pødenphant², Henrik Skjødt¹, Aage Vestergaard², Bo Jannik Ejbjerg¹, Søren Jacobsen¹, Niels Steen Krogh¹, Mikkel Ostergaard¹ and Kim Hørslev-Petersen², ¹Rigshospitalet (Glostrup and Blegdamsvej), Århus University Hospital, Odense University Hospital, Herlev/Gentofte Hospital, Slagelse Sygehus, Chr X hospital (University of South Denmark) and Zitelab Aps, DANBIO Registry and Departments of Rheumatology, Glostrup, Denmark, ²Rigshospitalet (Glostrup and Blegdamsvej), Århus University Hospital, Odense University Hospital, Herlev/Gentofte Hospital, Slagelse Sygehus, Chr X hospital (University of South Denmark) and Zitelab Aps, DANBIO Registry and Departments of Rheumatology, Copenhagen, Denmark
Background/Purpose: Few RCTs have investigated long-term (10+ years) outcomes of goal-directed synovitis suppression in early rheumatoid arthritis (RA). The CIMESTRA trial was a 2-year double-blinded…
Abstract Number: 3211 • 2016 ACR/ARHP Annual Meeting
Early Radiological Progression in Rheumatoid Arthritis Leads to More Long-Term Joint Damage in Daily Clinical Practice; Six Year Radiological Outcomes of a Strict Treat-to-Target Cohort in the Netherlands
Letty G.A. Versteeg¹, Laura M.M. Steunebrink¹, Ina H. Kuper¹, Harald E. Vonkeman², Peter M. ten Klooster³, Arie E. van der Bijl⁴ and Mart A.F.J. van de Laar⁵, ¹Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²koningsplein, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Pcgr, University of Twente, Enschede, Netherlands, ⁴Isala Klinieken, Zwolle, Netherlands, ⁵Rheumatology, Arthritis Centre Twente, Medisch Spectrum Twente and University Twente, Enschede, Netherlands
Background/Purpose: Implementation of treat-to-target (T2T) in Rheumatoid Arthritis (RA) leads to limited radiological damage during follow-up of 3 years. Questions are whether these results are…
Abstract Number: 3212 • 2016 ACR/ARHP Annual Meeting
Treat-to-Target in RA: Does Early Simplified Disease Activity Index (SDAI) Remission Lead to Better 5-Year Functional Outcomes Than SDAI Low Disease Activity?
Vibeke Norvang, Elisabeth Lie, Inge C Olsen, Eirik K Kristianslund, Tore K Kvien and Till Uhlig, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The management of rheumatoid arthritis (RA) has evolved considerably during the last couple of decades, with current recommended practice being a treat-to-target approach, involving…
Abstract Number: 3213 • 2016 ACR/ARHP Annual Meeting
Assessment of Two Different DAS Treatment Targets in Early Active Rheumatoid Arthritis Patients
Gülsah Akdemir¹, Iris M. Markusse², Yvonne P. Goekoop-Ruiterman³, J.B. Harbers⁴, Maikel van Oosterhout⁵, Pit J.S.M. Kerstens⁶, Willem F. Lems⁷, TWJ Huizinga⁸ and Cornelia F. Allaart², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, LUMC, Leiden, Netherlands, ³Rheumatology, HAGA hospital, The Hague, Netherlands, ⁴Department of Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, ⁵Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁶Department of Rheumatology, Reade, Amsterdam, Netherlands, ⁷Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ⁸Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: It remains to be determined if setting remission or low disease activity as treatment target affects significant outcomes in early active rheumatoid arthritis (RA)…
Abstract Number: 3214 • 2016 ACR/ARHP Annual Meeting
Implementation of Treat to Target in Rheumatoid Arthritis through a Learning Collaborative
Daniel H. Solomon¹, Bing Lu², Elena Losina³, Jen Agosti⁴, Agnes Zak⁵, Cassandra Corrigan⁵, Zhi Yu⁶, Sara Lee⁵, Asaf Bitton⁷, LR Harrold⁸, Theodore Pincus⁹, Helga Radner¹⁰, Josef Smolen¹¹, Liana Fraenkel¹² and Jeffrey N. Katz¹³, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ³Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopaedic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴JRA Consulting, Andover, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Medicine, Brigham and Women's Hospital, Boston, MA, ⁸University of Massachusetts Medical School, Worcester, MA, ⁹Rheumatology, Rush University Medical Center, Chicago, IL, ¹⁰Rheumatology, Medical University of Vienna, Vienna, Austria, ¹¹Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ¹²Yale University School of Medicine, New Haven, CT, ¹³Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Treat to target (TTT) is a recommended strategy in the management of rheumatoid arthritis (RA), but various studies suggest that its uptake in routine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].